LYMPHOSEEK KIT Drug Patent Profile
✉ Email this page to a colleague
When do Lymphoseek Kit patents expire, and when can generic versions of Lymphoseek Kit launch?
Lymphoseek Kit is a drug marketed by Cardinal Health 414 and is included in one NDA. There are two patents protecting this drug.
This drug has thirty patent family members in twelve countries.
The generic ingredient in LYMPHOSEEK KIT is technetium tc-99m tilmanocept. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the technetium tc-99m tilmanocept profile page.
DrugPatentWatch® Generic Entry Outlook for Lymphoseek Kit
Lymphoseek Kit was eligible for patent challenges on March 13, 2017.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 30, 2029. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LYMPHOSEEK KIT?
- What are the global sales for LYMPHOSEEK KIT?
- What is Average Wholesale Price for LYMPHOSEEK KIT?
Summary for LYMPHOSEEK KIT
| International Patents: | 30 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 24 |
| DailyMed Link: | LYMPHOSEEK KIT at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LYMPHOSEEK KIT
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LYMPHOSEEK KIT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| John O. Prior | Early Phase 1 |
| Stanford University | Phase 2 |
| Anna Cruceta | Phase 4 |
US Patents and Regulatory Information for LYMPHOSEEK KIT
LYMPHOSEEK KIT is protected by two US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of LYMPHOSEEK KIT is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting LYMPHOSEEK KIT
Macromolecular carrier for drug and diagnostic agent delivery
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
FDA Regulatory Exclusivity protecting LYMPHOSEEK KIT
NEW PATIENT POPULATION
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LYMPHOSEEK KIT
When does loss-of-exclusivity occur for LYMPHOSEEK KIT?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 10208624
Patent: Compositions for radiolabeling diethylenetriaminepentaacetic acid (DTPA)-dextran
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 1007487
Patent: composição para radiomarcar ácido dietilenotriaminopentacético (dtpa)-dextrano
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 50230
Patent: COMPOSITIONS DE RADIOMARQUAGE D'ACIDE DIETHYLENETRIAMINEPENTAACETIQUE (DTPA)-DEXTRAN (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Sign Up
China
Patent: 2301429
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 92012
Patent: COMPOSITIONS DE RADIOMARQUAGE D'ACIDE DIÉTHYLÈNETRIAMINEPENTAACÉTIQUE (DTPA)-DEXTRAN (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Sign Up
Patent: 84965
Patent: COMPOSITIONS DE RADIOMARQUAGE DE L'ACIDE DIÉTHYLÈNETRIAMINEPENTAACÉTIQUE (DTPA)-DEXTRAN (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 43905
Estimated Expiration: ⤷ Sign Up
Patent: 40276
Estimated Expiration: ⤷ Sign Up
Patent: 09796
Estimated Expiration: ⤷ Sign Up
Patent: 33892
Estimated Expiration: ⤷ Sign Up
Patent: 12516328
Estimated Expiration: ⤷ Sign Up
Patent: 15164933
Patent: ジエチレントリアミン五酢酸（ＤＴＰＡ）−デキストランを放射標識するための組成物 (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Sign Up
Patent: 17066148
Patent: ジエチレントリアミン五酢酸（ＤＴＰＡ）−デキストランを放射標識するための組成物 (COMPOSITION FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Sign Up
Patent: 19178133
Patent: ジエチレントリアミン五酢酸（ＤＴＰＡ）−デキストランを放射標識するための組成物 (COMPOSITIONS FOR RADIOLABELING DIETHYLENETRIAMINE PENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Sign Up
Patent: 21088566
Patent: ジエチレントリアミン五酢酸（ＤＴＰＡ）−デキストランを放射標識するための組成物 (COMPOSITIONS FOR RADIO-LABELLING DIETHYLENETRIAMINE PENTAACETIC ACID (DTPA)-DEXTRAN)
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1713559
Estimated Expiration: ⤷ Sign Up
Patent: 1765717
Estimated Expiration: ⤷ Sign Up
Patent: 110115148
Patent: COMPOSITION FOR RADIOLABELING DIETHYLENETRIAMINEPENTAACETIC ACID(DTPF)-DEXTRAN
Estimated Expiration: ⤷ Sign Up
Patent: 170027874
Patent: 방사성 식별을 위한 디티피에이 덱스트란 조성물 (composition for radiolabeling diethylenetriaminepentaacetic acidDTPF-dextran)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering LYMPHOSEEK KIT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 5270500 | ⤷ Sign Up | |
| Japan | 6833892 | ⤷ Sign Up | |
| Japan | 6509796 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LYMPHOSEEK KIT
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1178838 | 15C0033 | France | ⤷ Sign Up | PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: EU/1/14/955 20141121 |
| 1178838 | 1590025-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: TILMANOCEPT; REG. NO/DATE: EU/1/14/955 20141120 |
| 1178838 | 122015000033 | Germany | ⤷ Sign Up | PRODUCT NAME: TILMANOCEPT; REGISTRATION NO/DATE: C(2014) 8901 FINAL 20141119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
